Medpace, founded in 1992 and headquartered in Cincinnati, Ohio, is a global clinical research organization (CRO) dedicated to accelerating the development of safe and effective medical therapeutics. The company provides comprehensive support services to pharmaceutical, biotech, and medical device companies, leveraging its deep therapeutic expertise in areas such as oncology, cardiology, metabolic disease, endocrinology, and the central nervous system. Medpace operates in over 40 countries, emphasizing a high science and disciplined operating approach to meet regulatory requirements and advance medical innovations.

Notable figures affiliated with Medpace include August J. Troendle, who serves as CEO and Chairman of the Board of Directors. The company is publicly traded on the Nasdaq under the ticker MEDP and is a component of the S&P 400. Medpace has achieved significant milestones, including generating $1.46 billion in revenue in 2022 and employing approximately 5,400 people by 2023. Its impactful contributions to the clinical research industry have facilitated the global development of numerous medical therapeutics, underscoring its role as a pivotal player in advancing healthcare solutions.